Table 3.
Treatment and outcomes of EBV, CMV, Adenovirus infections
| UPN | Infection | Treatment | Response | F/U (mo) | Outcome | Day died | Cause of death | ||
|---|---|---|---|---|---|---|---|---|---|
| 1 | EBV | Rituximab | Resolved | 52.9 | |||||
| 2 | 45.5 | ||||||||
| 3 | Adenoviremia | Cidofovir CTL |
Resolved | Death | 170 | Hemolytic transfusion reaction | |||
| 4 | CMV viremia | Foscarnet, GCV | Resolved | AR | |||||
| 5 | 40.4 | ||||||||
| 6 | 35.4 | ||||||||
| 7 | 34.8 | ||||||||
| 8 | Adenoviremia | CMX001 | Resolved | 33.6 | |||||
| 9 | CMV viremia | Foscarnet, GCV | Resolved | 31.3 | |||||
| 10 | 30.9 | ||||||||
| 11 | Adenoviremia | Cidofovir CMX001 |
Death | GF | Death | 25 | Disseminated adenoviral infection | ||
| 12 | 26.6 | ||||||||
| 13 | Adenovirus | Cidofovir | Resolved | 26.4 | |||||
| 14 | Adenovirus | Cidofovir CTL |
Death | Death | 24 | Adenoviremia, Parainfluenza 3 | |||
| 15 | AR | ||||||||
| 16 | EBV | Rituximab | Resolved | 16.4 | |||||
| 17 | Adenoviremia | CMX001 | Ongoing treatment due to chronic GVHD | 15.9 | |||||
| 18 | 15.5 | ||||||||
| 19 | 15.3 | ||||||||
| 20 | Adenoviremia | Cidofovir | 14.3 | ||||||
| 21 | CMV viremia | Foscarnet, GCV | Death | Death | 27 | CMV pneumonia | |||
| 22 | Adenoviremia CMV |
Cidofovir CMX001 |
Death | Death | 258 | Acute GVHD, adenoviremia, CMV | |||
F/U = follow-up; CTL = Trivirus (adenovirus, CMV, EBV) specific cytotoxic T lymphocytes